gynipral infusioonilahuse kontsentraat
takeda austria gmbh - heksoprenaliin - infusioonilahuse kontsentraat - 5mcg 1ml 5ml 25tk; 5mcg 1ml 2ml 25tk; 5mcg 1ml 5ml 5tk
gynipral süstelahus
takeda austria gmbh - heksoprenaliin - süstelahus - 5mcg 1ml 2ml 5tk
datscan
ge healthcare b.v. - ioflupaan (123l) - tomography, emission-computed, single-photon; lewy body disease; parkinson disease; alzheimer disease - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. datscan on näidustatud avastada kaotus funktsionaalne dopaminergic neuron terminalide striatum:täiskasvanud patsientidel, kellel on kliiniliselt ebakindel parkinsonian sündroomid, näiteks need, kellel on varajased sümptomid, et aidata eristada oluline värin alates parkinsonian sündroomid, mis on seotud idiopaatiline parkinsoni tõbi, sclerosis süsteemi atroofia ja progressiivne supranuclear halvatus. datscan on suutnud teha vahet parkinsoni tõbi, sclerosis süsteemi atroofia ja progressiivne supranuclear halvatus. täiskasvanud patsientidel, et aidata eristada arvatav dementsus koos lewy kehad alzheimeri tõbi. datscan on suutnud teha vahet dementsus koos lewy kehad ja parkinsoni tõbi, dementsus.
tyenne
fresenius kabi deutschland gmbh - totsilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosupressandid - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.
ybersigax 150 mg õhukese polümeerikattega tablett
galex d.d. - irbesartaan - õhukese polümeerikattega tablett - 150mg 30tk; 150mg 56tk; 150mg 90tk; 150mg 28tk; 150mg 84tk; 150mg 14tk
ybersigax 300 mg õhukese polümeerikattega tablett
galex d.d. - irbesartaan - õhukese polümeerikattega tablett - 300mg 90tk; 300mg 28tk; 300mg 30tk; 300mg 56tk; 300mg 84tk; 300mg 14tk
doxyprim 40% suukaudse lahuse pulber
lavet pharmaceuticals ltd. - doksütsükliin - suukaudse lahuse pulber - 400mg 1g 10000g 1tk; 400mg 1g 1000g 1tk; 400mg 1g 5000g 1tk
amoxyn 100% suukaudse lahuse pulber
lavet pharmaceuticals ltd. - amoksitsilliin - suukaudse lahuse pulber - 1000mg 1g 100g 1tk
lamulin 45% suukaudse lahuse graanulid
lavet pharmaceuticals ltd. - tiamuliin - suukaudse lahuse graanulid - 364,2mg 1g 1000g 1tk; 364,2mg 1g 5000g 1tk
mucosiffa süstesuspensiooni lüofilisaat ja lahusti
ceva-phylaxia zrt. - veiste viirusdiarröa viirusvaktsiin - süstesuspensiooni lüofilisaat ja lahusti - 1annus 1tk; 50annus 1tk; 5annus 1tk; 10annus 1tk; 20annus 1tk